Business Description
Nexentis Technologies Inc. develops and operates an AI and data-driven computational biotech platform. It focuses on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. The company biotechnology segment, driven by its proprietary MITOLINE discovery engine and structure-guided virtual screening workflows, is engaged in the discovery and development of small-molecule therapeutics targeting the mitochondrial SLC25 carrier family for resistant cancers and inflammatory metabolic disease indications. The company’s pipeline includes preclinical programs for oncology and metabolic-inflammation, with evidence supporting anti-tumor and anti-inflammatory activity in human-relevant systems. The renewable energy investments segment manages non-core, value-optimizing assets, including investments in solar energy projects across multiple european union countries, utilizing a ready to build business model. In addition, the company provides post-harvest treatment technologies for reducing pathogen contamination in fruits and vegetables. It serves customers in the biotechnology, pharmaceutical, and renewable energy sectors, as well as the agricultural industry. The company operates internationally, with a particular focus on the European Union and Israel. The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.
Business History
Price Overview
Last updated: Jun 27, 2026 10:09am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -3.54
Total Equity: $16.01M
Shares: 1,288,249,000
Total Debt: $748,000
Cash: $3.83M
EBITDA: -$3.42M
Total Debt: $748,000
Cash: $3.83M
Revenue: $0.00
Shares: 1,288,249,000
Revenue: $0.00
Revenue: $0.00
Revenue: $0.00
Total Equity: $16.01M
Tax Rate: 0.5%
Equity: $16.01M
Total Debt: $748,000
Cash: $3.83M
Current Liabilities: $1.43M
Long-Term Debt: $8,000
Total Debt: $748,000
Total Equity: $16.01M
Shares: 1,288,249,000
Shares: 1,288,249,000
CapEx: -$14,000
Shares: 1,288,249,000
Stock Price: $4.97
Net Income: -$4.00M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 9:13am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $438,141 | $394,004 | $263,445 | $210,000 | $0 |
| Cost of Revenue | $135,943 | $158,313 | $55,178 | $165,000 | $79,000 |
| Gross Profit | $302,198 | $235,691 | $208,267 | $45,000 | $-79,000 |
| Operating Expenses | $5.0M | $6.1M | $7.8M | $4.4M | $5.0M |
| Operating Income | -$4.7M | -$5.8M | -$7.6M | -$4.3M | -$5.0M |
| Net Income | -$4.8M | -$5.7M | -$6.5M | -$5.2M | -$4.0M |
| EBITDA | -$4.8M | -$5.7M | -$7.5M | -$5.2M | -$3.4M |
| EPS | $-504.00 | $-379.75 | $-190.05 | $-31.15 | $-3.54 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 9:13am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.8M | $5.7M | $4.5M | $2.2M | $3.8M |
| Total Current Assets | $7.2M | $6.3M | $5.5M | $3.4M | $6.0M |
| Total Assets | $7.6M | $6.5M | $7.2M | $5.5M | $20.4M |
| Current Liabilities | $931,304 | $714,849 | $778,472 | $892,000 | $1.4M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $8,000 |
| Total Liabilities | $1.2M | $754,872 | $785,653 | $892,000 | $4.7M |
| Total Equity | $6.5M | $5.8M | $6.5M | $4.7M | $16.0M |
| Retained Earnings | -$17.1M | -$22.8M | -$29.4M | -$34.6M | -$38.6M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 9:13am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$4.1M | -$5.1M | -$3.2M | -$3.4M | -$3.8M |
| Capital Expenditure | $-67,753 | $-51,689 | $-1 | $0 | $-14,000 |
| Free Cash Flow | -$4.2M | -$5.1M | -$3.2M | -$3.4M | -$3.8M |
| Acquisitions (net) | $0 | $0 | $22,789 | -$1.0M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $6.5M | -$1.1M | -$1.3M | -$2.3M | $1.8M |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 9:13am (6d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -10.1% | -33.1% | -20.3% | -100.0% |
| Gross Profit Growth | -22.0% | -11.6% | -78.4% | -275.6% |
| Operating Income Growth | -23.7% | -30.2% | +43.0% | -16.4% |
| Net Income Growth | -19.1% | -13.6% | +20.4% | +22.9% |
| EBITDA Growth | -19.1% | -31.5% | +30.3% | +34.7% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-02-09 | Zakai Shlomo | A-Award | 50,000.00 | $0.00 | $0 |
| 2026-02-09 | Barda Lital | A-Award | 50,000.00 | $0.00 | $0 |
| 2026-02-09 | Weiss Amitay | A-Award | 116,286.00 | $0.00 | $0 |
| 2026-02-09 | Palach David | A-Award | 100,000.00 | $0.00 | $0 |
| 2025-10-20 | Silberman Alon | 0.00 | $0.00 | $0 | |
| 2025-10-20 | Silberman Alon | 146,493.00 | $0.00 | $0 | |
| 2025-10-20 | SciSparc Ltd. | 0.00 | $0.00 | $0 | |
| 2025-05-12 | Barda Lital | A-Award | 300,000.00 | $0.00 | $0 |
| 2025-05-12 | Palach David | A-Award | 600,000.00 | $0.00 | $0 |
| 2024-12-23 | Rosenbloom Ronen | P-Purchase | 50,000.00 | $0.00 | $0 |
| 2024-12-23 | Itzhaik Asaf | A-Award | 50,000.00 | $0.00 | $0 |
| 2024-12-23 | Kalifi Udi Ovadia | A-Award | 50,000.00 | $0.00 | $0 |
| 2024-12-23 | Weiss Amitay | A-Award | 350,000.00 | $0.00 | $0 |
| 2024-12-23 | Berenstein Israel Yakov | A-Award | 50,000.00 | $0.00 | $0 |
| 2024-12-23 | Sidi Liat | A-Award | 50,000.00 | $0.00 | $0 |
| 2024-12-23 | Arbib Eliahou | A-Award | 50,000.00 | $0.00 | $0 |
| 2024-09-12 | Barda Lital | A-Award | 160,000.00 | $0.00 | $0 |
| 2024-09-12 | Palach David | A-Award | 320,000.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).